// App-Quantinova.ai

3140 : Acalabrutinib Vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Ascend Final Results

Researchers

Presenter

  • Paolo Ghia

Principal Investigators

  • Andrzej Pluta

  • Malgorzata Wach

  • Daniel Lysak

  • Tomas Kozak

  • Martin imkovic

  • Iryna Kryachok

  • rpd Ills

  • Javier de la Serna

  • Sean Dolan

  • Philip Campbell

  • Gerardo Musuraca

  • Abraham Jacob

  • Eric J. Avery

  • Jae Hoon Lee

  • Denise Wang

  • Priti Patel

  • Wojciech Jurczak

Medical Centers

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Department of Hematological Oncology, Oncology Spec. Hospital, Brzozow, Poland

  • Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St John's Cancer Center, Lublin, Poland

  • Fakultní Nemocnice Plzen,Pilsen,Czech

  • Fakultní Nemocnice Královske Vinohrady, Prague, Czech Republic

  • University Hospital Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic

  • National Cancer Institute, Kiev, Ukraine

  • Institute of Internal Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Saint John Regional Hospital, University of New Brunswick, New Brunswick, Canada

  • Barwon Health, University Hospital Geelong,Victoria,Australia

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • The Royal Wolverhampton NHS Trust,Wolverhampton, UK

  • Nebraska Hematology Oncology, Lincoln, NE

  • Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)

  • Acerta Pharma, South San Francisco, CA

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

Locations

  • Italy

  • Poland

  • Czech Republic

  • Ukraine

  • Hungary

  • Spain

  • Canada

  • Australia

  • United Kingdom

  • United States

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • ACP-196

  • Bendamustine

  • Idelalisib

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02970318

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved